Rapid and durable complete response in patients with newly diagnosed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone
Drug combination, with a next generation proteasome inhibitor, highly effective for newly diagnosed myeloma patients
- Date : 12 Jun 2012
- Topic : Melanoma
A three-drug treatment for multiple myeloma provided rapid, deep and potentially durable responses, researchers reported on June 4 online in Blood, the journal of the American Society of Haematology, and June 3 at the 2012 Annual Meeting of American Society of Clinical Oncology (Chicago, USA).
The researchers, led by Dr Andrzej Jakubowiak, professor of medicine and director of the multiple myeloma programme at the University of Chicago Medical Center, found that combining carfilzomib, a next generation proteasome inhibitor, with two standard drugs, lenalidomide and low-dose dexamethasone, compared favourably to other frontline regimens.
The longer patients stayed on the therapy, the better their response. After at least eight 4-week cycles of treatment, 61% of the 36 patients who remained on the therapy had a stringent complete response, defined as no detectable tumour cells or myeloma protein in the blood or bone marrow; 78% had at least a near complete response. More than 90% of patients had no progression of their disease at two years.
Rapid and durable response rates higher than those achieved by the best established regimens
The study researchers have observed excellent efficacy, the best reported to date, and very good tolerability, including limited peripheral neuropathy that has been problematic with other drug combinations.
The research team enrolled 53 patients with newly diagnosed myeloma in the trial at four centres. Patients, aged 35 to 81, all had newly diagnosed multiple myeloma. Every patient received all three drugs and the carfilzomib dose levels were increased twice for new patients as the study progressed. Most patients responded rapidly to the combination and continued to improve.
Newly diagnosed patients with myeloma are most sensitive to treatment. A rapid and sustained response to the initial phase of treatment, as in the case of this study, can typically project longer remission, and, possibly, longer overall survival.
The Multiple Myeloma Research Consortium, Onyx Pharmaceuticals Inc., Celgene Corp. and the University of Michigan funded the study.
Thank you for rating!
You have already rated this page, you can only rate it once!